Medicinova Inc
Medicinova Inc (MNOV) Straddle
MNOV straddle scan found 6 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 75.8%.
Read more
Trading a MNOV straddle lets you take a pure volatility position on Medicinova Inc without committing to a direction. Medicinova Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate MNOV straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on MNOV profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Medicinova Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the MNOV straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers.
The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the MNOV straddle is the cleanest expression of that view. Our scanner prices every MNOV straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a MNOV straddle into a catalyst or short a MNOV straddle to harvest decay, the options straddle setups that matter are all in one place.
| Apr 16, 2027 | 5.00 | $3.18 | 205 | 77% | 75.8% | $8.18 | $1.83 | 0 |
| Jan 15, 2027 | 2.50 | $1.33 | 114 | 77% | 62.7% | $3.83 | $1.18 | 11 |
| Oct 16, 2026 | 5.00 | $2.35 | 23 | 77% | 57.6% | $7.35 | $2.65 | 102 |
| Apr 16, 2027 | 2.50 | $1.90 | 205 | 77% | 55.2% | $4.40 | $0.60 | 0 |
| Oct 16, 2026 | 2.50 | $1.10 | 23 | 77% | 36.8% | $3.60 | $1.40 | 121 |
| Nov 20, 2026 | 2.50 | $1.63 | 58 | 77% | 34.6% | $4.13 | $0.88 | 0 |
As of September 24, 2026
Find the right straddle before volatility moves
Track MNOV straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→